RNA: I don't think that there will be any specific events. Instead:
1. Good pipeline. At least three other programs with very promising drugs.
2. In their CC they said that the drug that performed poorly in the recent test—drisapersen—which caused the recent radical decline in stock price, was designed over 10 years ago and their other drugs were designed more recently, and they’ve learned a lot.
3. Even though drisapersen did not do well in the P3 trial, they can still file with the EMA based on two good P3’s.
4. Still partnered with GSK.
5. They are in a good niche—orphan diseases.
6. They have plenty of cash and a bright future, they’re not folding up their tent and calling it quits.
Again, there’s no single event that’s going to occur in the near future, instead it’s simply going to be a cessation of all this panic dumping and a realization by both retail and institutional buyers that the risk-reward at this price is fantastic.
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius
